<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04325373</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2020/07</org_study_id>
    <nct_id>NCT04325373</nct_id>
  </id_info>
  <brief_title>Abdominal Aortic Aneurysm Surgery and Thrombosis</brief_title>
  <acronym>AAA-IT</acronym>
  <official_title>Study of Thrombotic Complications After Abdominal Aortic Aneurysm Surgery With or Without Infection: AAA-IT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to evaluate the incidence of post-operative thrombotic complications
      after abdominal aortic aneurysm surgery in the context of atherosclerosis or infectious
      aneurysm and its links with preoperative inflammation and hemostasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abdominal aortic aneurysm (AAA) develops in the context of atherosclerosis or infection
      (aortitis or mycotic aneurysm). AAA and its surgery are associated with pro-thrombotic
      modifications of hemostasis, which persists in the post-operative period. Pro-thrombotic
      reactions occur in the intraluminal thrombus. Inflammatory cells recruitment is mediated by
      adhesion molecules from the activated endothelium, such as &quot;vascular cell adhesion
      molecule-1&quot; (VCAM-1), &quot;intercellular adhesion molecule-1&quot; (ICAM-1), P-selectin and
      E-selectin.

      In the setting of infection, neutrophil death process occurs, the NETosis, with the
      liberation of Neutrophil Extracellular Traps (NETs), containing DNA and histones. NETs are
      associated with thrombosis and various studies have already quantified NETosis biomarkers in
      plasma from patients with thrombotic disease, such as MPO-DNA (DNA coupled myeloperoxidase).

      In the clinical perioperative setting, patients with aortitis scheduled for AAA surgery
      shwoed exhibit thrombotic events.

      The hypothesize was that patients with aortitis have an inflammatory and hemostatic
      activation different from patients who develop AAA in atherosclerotic condition, and that
      inflammation is a risk factor of postoperative thrombotic events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>thrombotic events</measure>
    <time_frame>first 7 postoperative days after AAA surgery</time_frame>
    <description>Incidence of thrombotic events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>white blood cells</measure>
    <time_frame>baseline</time_frame>
    <description>white blood cells (G/L),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin</measure>
    <time_frame>baseline</time_frame>
    <description>hemoglobin (g/dL),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelets</measure>
    <time_frame>baseline</time_frame>
    <description>platelets (G/L),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prothrombin time ratio</measure>
    <time_frame>baseline</time_frame>
    <description>prothrombin time ratio (%),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INR</measure>
    <time_frame>baseline</time_frame>
    <description>INR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aPTT ratio</measure>
    <time_frame>baseline</time_frame>
    <description>aPTT ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fibrinogen</measure>
    <time_frame>baseline</time_frame>
    <description>fibrinogen (g/L),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>baseline</time_frame>
    <description>CRP (ng/mL),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin-6</measure>
    <time_frame>baseline</time_frame>
    <description>interleukin-6 (pg/mL),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thrombin generation test</measure>
    <time_frame>baseline</time_frame>
    <description>thrombin generation test (lag time (min),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak</measure>
    <time_frame>baseline</time_frame>
    <description>peak (nM),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to peak</measure>
    <time_frame>baseline</time_frame>
    <description>time to peak (min),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ETP</measure>
    <time_frame>baseline</time_frame>
    <description>ETP (nM.min),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>velocity index</measure>
    <time_frame>baseline</time_frame>
    <description>velocity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>von Willebrand factor</measure>
    <time_frame>baseline</time_frame>
    <description>von Willebrand factor (%),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>soluble P-selectin</measure>
    <time_frame>baseline</time_frame>
    <description>soluble P-selectin (ng/mL),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPO-AND</measure>
    <time_frame>baseline</time_frame>
    <description>MPO-AND (% standard)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>atherosclerosis</measure>
    <time_frame>baseline</time_frame>
    <description>% of patients with preoperative atherosclerosis (number)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspirin treatment</measure>
    <time_frame>baseline</time_frame>
    <description>% of patients with preoperative treatment by Aspirin (number)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clamping duration</measure>
    <time_frame>baseline</time_frame>
    <description>clamping duration (min),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding</measure>
    <time_frame>baseline</time_frame>
    <description>bleeding (min),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vascular filling</measure>
    <time_frame>baseline</time_frame>
    <description>vascular filling (ml),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tranexamic acid administration</measure>
    <time_frame>baseline</time_frame>
    <description>tranexamic acid administration (g),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transfusion</measure>
    <time_frame>baseline</time_frame>
    <description>transfusion (pack of red blood cells, plasma volume (ml),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of fibrinogen</measure>
    <time_frame>baseline</time_frame>
    <description>amount of fibrinogen (g),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of heparin</measure>
    <time_frame>baseline</time_frame>
    <description>amount of heparin (UI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of postoperative anticoagulation</measure>
    <time_frame>baseline</time_frame>
    <description>Type of postoperative anticoagulation: % of patients with unfractionated heparin or low-molecular-weight heparin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration way of postoperative anticoagulation</measure>
    <time_frame>Baseline</time_frame>
    <description>Administration way of postoperative anticoagulation: % of administration intra-venous or subcutaneously</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Abdominal Aortic Aneurysm</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with surgery for abdominal aortic aneurysm
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient &gt;18 years-old;

          -  patient scheduled for AAA surgery by laparotomy in the vascular surgical unit at
             Bordeaux University Hospital;

          -  patient who gave his/her authorization for the use of its medical data and results of
             blood analyses performed on residual plasma and results of aortic material analyses

        Exclusion Criteria:

          -  patient who do not understand the study (not fluently French speaking or unable to
             give his/her consent);

          -  patient with a pre-existing hemostatic disorder;

          -  patient scheduled for an endovascular surgery and benefiting from a secondary
             laparotomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Stephanie Roullet, MD</last_name>
    <phone>+33556795628</phone>
    <email>stephanie.roullet@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Roullet, MD</last_name>
      <email>stephanie.roullet@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>abdominal aortic aneurysm</keyword>
  <keyword>NETosis</keyword>
  <keyword>thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

